CurrentWellCarePolicy CP.MP.108

Allogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and β‑Thalassemia

Customize your policy alerts

Sign up for WellCare Policy CP.MP.108 alerts

Get alerted when Policy CP.MP.108 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Medical necessity criteria and coverage stance for allogeneic hematopoietic cell transplantation (HCT) to treat sickle cell anemia and homozygous β‑thalassemia for members of WellCare-affiliated health plans; intended for providers requesting transplant authorization and utilization review.

Policy Summary

PayerWellCare

PolicyAllogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and β‑Thalassemia

Policy CodePolicy CP.MP.108

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain prior authorization with documentation that the candidate meets the policy's medical necessity criteria, including age, HLA match/donor relationship, and disease-specific clinical history.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≤45max age

1st‑degree HLA‑matchedpreferred donor (sickle cell)

transfusion‑dependentthalassemia requirement

85–90%pediatric success rate

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentWellCarePolicy CP.MP.108

Allogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and β‑Thalassemia

Customize your policy alerts

Sign up for WellCare Policy CP.MP.108 alerts

Get alerted when Policy CP.MP.108 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerWellCare

PolicyAllogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and β‑Thalassemia

Policy CodePolicy CP.MP.108

Change TypeNo material changes

Effective Date

Next Review Date

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≤45max age

1st‑degree HLA‑matchedpreferred donor (sickle cell)

transfusion‑dependentthalassemia requirement

85–90%pediatric success rate

65–90%thalassemia survival

Medical Necessity and Coverage Criteria

Medical necessity criteria — Sickle cell anemia and Homozygous β-thalassemia

Covered when ALL of the following are met for each condition-specific branch

Sickle Cell Anemia coverage criteria: All of: (1) Age ≤ 45 years; (2) HLA-matched, first-degree relative donor is available; (3) History of stroke or is at risk of stroke or end-organ damage, demonstrated by at least one of: prior stroke, recurrent acute chest syndrome, recurrent vasoocclusive crises, or red blood cell alloimmunization on chronic transfusion therapy.

Homozygous β-Thalassemia coverage criteria: All of: (1) Age ≤ 45 years; (2) HLA-matched donor available with one of: (a) cord blood is the source and donor is a first-degree relative, (b) bone marrow is the source, (c) peripheral blood is the source and the donor is unable or refuses to donate bone marrow; (3) Transfusion-dependent due to thalassemia; (4) A standard, myeloablative conditioning regimen will be used; (5) Request is made by, or in consultation with, a provider specializing in treating thalassemia.

Absolute contraindications

Absolute contraindications (must NOT have any to be eligible)

Absolute contraindications: Any of: (1) Infections with highly virulent and/or resistant microbes that are poorly controlled pre-transplant; (2) Inability to adhere to the regimen necessary to preserve the transplant, even with caregiver support; (3) Active substance use or dependence including current tobacco use, vaping, marijuana use (unless prescribed by a licensed practitioner), or IV drug use without convincing evidence of risk reduction behaviors (exceptions allowed for urgent transplant timelines when a commitment to reducing behaviors is present).

Autologous hematopoietic cell transplant for sickle cell anemia or β-thalassemia outside of a gene therapy context is considered to have insufficient evidence regarding safety and efficacy and is not supported by this policy.

Allogeneic hematopoietic cell transplantation (HCT) performed for indications other than those explicitly listed in this policy is considered to have insufficient evidence of safety and efficacy. Requests for allogeneic HCT must meet the condition-specific medical necessity criteria (see policy sections for sickle cell anemia and homozygous β-thalassemia) to be considered covered.

Coverage of hematopoietic cell transplantation is subject to the Health Plan's applicable plan-level exclusions, limitations, and administrative policies. Coverage decisions are governed by the terms and conditions of the member's benefit documents and by state and federal legal and regulatory requirements. When state Medicaid provisions conflict with this clinical policy, the state Medicaid provisions take precedence.

Candidate Eligibility Requirements

Condition-specific candidate requirements

Sickle cell candidate nodes: Age ≤ 45 years; HLA-matched first-degree relative donor available; history of stroke or other high-risk features (prior stroke, recurrent acute chest syndrome, recurrent vasoocclusive crises, or red blood cell alloimmunization on chronic transfusion therapy).

β-thalassemia candidate nodes: Age ≤ 45 years; HLA-matched donor available with acceptable stem cell source per policy (cord blood from a first-degree relative, bone marrow, or peripheral blood if donor unable/refuses bone marrow); transfusion-dependent due to thalassemia; myeloablative conditioning regimen planned; request by, or in consultation with, a thalassemia specialist.

Contraindications

Absolute contraindications that must NOT be present for transplant eligibility include: (1) infections with highly virulent and/or resistant microbes that are poorly controlled pre-transplant; (2) an inability to adhere to the required transplant regimen even with caregiver support; and (3) active substance use or dependence—including current tobacco use, vaping, marijuana use (unless prescribed), or intravenous drug use—without convincing evidence of risk-reduction behaviors (exceptions may be considered when urgent transplant timelines exist and a commitment to risk reduction is documented).

No additional contraindications are specified in this portion of the document.

Pre-Transplant Evaluation Requirements

Documentation Required

Evaluation: document age, HLA match, donor source/relationship, and disease‑specific status

Before requesting prior authorization or scheduling transplant, document in the pre‑transplant evaluation: (1) patient age to confirm eligibility (age ≤ 45 years for both sickle cell anemia and homozygous β‑thalassemia); (2) HLA matching and the donor relationship/source (for sickle cell: HLA‑matched first‑degree relative; for β‑thalassemia: HLA‑matched donor with acceptable source per policy — cord blood from a first‑degree relative, bone marrow, or peripheral blood if marrow donation is not possible); and (3) disease‑specific status — transfusion‑dependence for β‑thalassemia or the specified clinical history for sickle cell (prior stroke, recurrent acute chest syndrome, recurrent vasoocclusive crises, or red blood cell alloimmunization on chronic transfusion therapy).

Record exact date of birth/age to confirm age ≤ 45 years.
Record HLA match testing results and specify donor relationship (first‑degree relative when required) and stem cell source.
For β‑thalassemia, document transfusion‑dependence due to thalassemia.
For sickle cell anemia, document history of prior stroke or other qualifying high‑risk features (recurrent acute chest syndrome, recurrent vaso‑occlusive crises, or red blood cell alloimmunization on chronic transfusion therapy).

Provider Responsibilities and Prior Authorization

Prior Authorization

Prior authorization required with supporting clinical documentation

Prior authorization is required and must demonstrate the candidate meets the policy's medical necessity criteria; include applicable procedure coding for hematopoietic progenitor cell harvesting and transplantation when submitting the request.

Include documentation that the candidate meets all listed coverage criteria (age ≤ 45, donor availability, condition-specific requirements, etc.).
Supply applicable CPT/HCPCS procedure codes such as 38205, 38240, and S2150 as relevant to the transplant and harvesting services.

Note

Prior authorization guidance and policy purpose

This clinical policy is intended to guide medical necessity determinations and assist in administering benefits; prior authorization is implied as part of plan-level administrative policies and procedures.

Transplant Procedure and Related Codes

Informational transplant procedure codesCPT | HCPCS

38205	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic.
38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor.
S2150	Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and posttransplant care in the global definition.

Post-Transplant Services and Coverage

Global transplant-related services (S2150)

HCPCS S2150 descriptionBone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; includes pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and posttransplant care in the global definition.

Included elements referencedDrugs, supplies, hospitalization, outpatient follow-up, pheresis and cell preparation/storage, marrow ablative therapy, and pre- and posttransplant care days.

Scope of S2150Covers harvesting, transplantation, related complications, and the global period components associated with transplant services.

Post-transplant coverage governance

Post-transplant coverage governancePost-transplant coverage details are governed by the Health Plan's administrative policies and applicable regulatory requirements and are not specified in this clinical policy.

Definitions and Terminology

Hematopoietic cell transplantation (HCT) — definition

DefinitionTransplantation of hematopoietic stem/progenitor cells from a donor to establish donor-derived erythropoiesis.

Therapeutic intentRecognized as a curative therapy for selected patients with sickle cell disease and β-thalassemia.

Cell sourcesDonor-derived hematopoietic stem/progenitor cells (bone marrow, peripheral blood, or cord blood) are used to reconstitute hematopoiesis.

Hematopoietic cell transplantation (HCT) — procedures & strategies

Clinical applicationAllogeneic HCT is used as a treatment option for sickle cell disease and β-thalassemia, with procedures and strategies described in the referenced literature.

Literature basisProcedures and strategies are informed by peer-reviewed articles and expert guidance on allogeneic transplantation, haploidentical approaches, and management recommendations.

Transplant Center Requirements

Billing Rule

Center/coding guidance: reference CPT/HCPCS (no explicit center requirements)

Providers should reference CPT and HCPCS coding guidance when preparing claims; the policy includes informational transplant procedure codes but does not specify center accreditation or volume requirements.

Use current CPT guidance prior to claim submission; included informational codes: 38205, 38240, and S2150.
The policy's coding section is informational and does not guarantee coverage.

Note

Center requirements: not specified

No additional center requirements are specified in this portion of the document.

Clinical Background

Sickle cell anemia and homozygous β-thalassemia are monogenic hemoglobinopathies that cause defective red blood cell function and significant morbidity. For selected patients, allogeneic hematopoietic cell transplantation (HCT) is recognized as a curative treatment modality. Candidate selection differs by condition: sickle cell transplant considerations include age limits and history of stroke or recurrent severe complications, while β-thalassemia selection emphasizes transfusion dependence, age, iron-overload related organ risk, and use of a myeloablative conditioning regimen with specialist consultation as specified in policy criteria.

Policy Ownership and Revision History

This clinical policy is the property of Centene Corporation and was developed by experienced licensed clinicians to guide medical necessity determinations for allogeneic HCT in sickle cell anemia and homozygous β-thalassemia. It is intended to assist in coverage decision-making and does not constitute a contract or guarantee of payment. Coverage determinations remain subject to the Health Plan's benefit documents and applicable laws and regulations. Policy identifier: CP.MP.108.

Policy Summary

PayerWellCare

PolicyAllogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and β‑Thalassemia

Policy CodePolicy CP.MP.108

Change TypeNo material changes

Effective Date

Next Review Date

SourceLink

On This Page

Note

Evaluation: other requirements not specified

No additional evaluation requirements are specified in this portion of the policy.

Documentation Required

Required documentation to support medical necessity

Documentation submitted with the authorization request must support patient age, HLA match and donor relationship, and the relevant clinical history (for sickle cell: stroke, recurrent acute chest syndrome, recurrent vaso‑occlusive crises, or RBC alloimmunization on chronic transfusion therapy; for β-thalassemia: transfusion-dependence), and should specify the planned conditioning regimen and specialist consultation when required.

Document patient age to confirm ≤ 45 years.
Provide evidence of HLA match and donor relationship/source.
Include clinical history supporting indication (stroke, recurrent ACS, recurrent VOCs, RBC alloimmunization, or transfusion dependence).
State planned conditioning regimen (myeloablative when required) and include thalassemia specialist consultation if applicable.

Note

Provider responsibility and plan/legal precedence

Providers must exercise professional medical judgment in caring for members; coverage is subject to the Health Plan's terms, conditions, exclusions, limitations, and applicable legal and regulatory requirements.

For Medicaid members, state Medicaid provisions take precedence where they conflict with this policy.
For Medicare members, review applicable NCDs/LCDs/Coverage Articles as needed.

Denial Risk

Denial risk if medical necessity criteria are incomplete

Requests that do not meet all listed medical necessity criteria (including age limit, donor availability and match, disease‑specific requirements, planned conditioning regimen where specified, and absence of absolute contraindications) risk denial.

Ensure all condition-specific criteria are documented: age ≤ 45, appropriate donor availability/source, clinical indications for transplant, and planned conditioning.
Verify absence of any absolute contraindication prior to submission.

Note

Coverage subject to plan terms, exclusions, and legal requirements

Coverage decisions and the administration of benefits are governed by the coverage documents and applicable state and federal requirements; discrepancies defer to law/regulation and plan-level terms, conditions, exclusions and limitations.

Policy roleThis clinical policy provides guidance for medical necessity and assists in coverage decision-making but does not guarantee payment or define plan-level benefits.

State/federal precedenceIf state Medicaid provisions conflict with this clinical policy, the state provisions take precedence (coverage subject to law/regulation).

ConsiderationsTransplant approaches differ by disease: conditioning intensity, donor source selection, and management of transplant-related complications are guided by clinical evidence and expert consensus.